San Diego, CA -- (SBWIRE) -- 02/22/2017 -- The acquisition of Zeltiq Aesthetics Inc is under investigation over potential wrongdoing. The investigation was announced on behalf of investors, who currently hold NASDAQ:ZLTQ shares concerning whether the takeover of Zeltiq Aesthetics Inc by Allergan plc for $56.50 per share is unfair.

Investors who purchased shares of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) and currently hold any of those NASDAQ:ZLTQ shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain directors of Zeltiq Aesthetics Inc breached their fiduciary duties owed to NASDAQ:ZLTQ investors in connection with the proposed acquisition.

On February 13, 2017, Allergan plc (NYSE:AGN) and ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ) announced that they have entered into an agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary adjustments.

However, the investigation concerns whether the offer is unfair to NASDAQ:ZLTQ stockholders. More specifically, the investigation concerns whether the Zeltiq Aesthetics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On February 21, 2017, NASDAQ:ZLTQ shares closed at $55.28 per share.

Those who are current investors in Zeltiq Aesthetics Inc shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com